Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial
Background: Haematoma expansion leads to worse outcome in intracerebral haemorrhage (ICH). Tranexamic acid (TXA) is a promising haemostatic agent to prevent haematoma expansion and improve outcome after ICH. Methods: TICH-2 is a multicentre prospective double blind randomised controlled trial, whic...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Conference or Workshop Item |
| Published: |
2018
|
| Online Access: | https://eprints.nottingham.ac.uk/51139/ |
| _version_ | 1848798426588774400 |
|---|---|
| author | Sprigg, Nikola Flaherty, Katie Law, Zhe Kang Appleton, Jason P. Scutt, Polly Krishnan, Kailash Bath, Philip M. |
| author_facet | Sprigg, Nikola Flaherty, Katie Law, Zhe Kang Appleton, Jason P. Scutt, Polly Krishnan, Kailash Bath, Philip M. |
| author_sort | Sprigg, Nikola |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Background: Haematoma expansion leads to worse outcome in intracerebral haemorrhage (ICH). Tranexamic acid (TXA) is a promising haemostatic agent to prevent haematoma expansion and improve outcome after ICH.
Methods: TICH-2 is a multicentre prospective double blind randomised controlled trial, which recruited patients presenting within 8 hours of primary ICH to receive intravenous TXA or placebo. Primary outcome is modified Rankin Scale at day 90 and will be analysed using ordinal logistic regression, adjusted for minimisation criteria. Secondary outcomes will be analysed using adjusted binary logistic regression and multiple linear regression; these include haematoma expansion at 24 hours, day 7 National Institute of Health Stroke Scale (NIHSS), day 90 Barthel Index, quality of life, cognition and mood.
Results: A total of 2325 patients were recruited between 14th March 2013 and 30th September 2017, from 12 countries: United Kingdom (n= 1910), Italy, Georgia, Switzerland, Malaysia, Hungary, Poland, Ireland, Turkey, Sweden, Denmark and Spain. Randomisation characteristics included: age 68.9 (13.8) years; male 1301 (56.0%); time from onset to randomisation 3.6 hours [2.6, 5.0]; NIHSS 13 (7.5); Glasgow coma scale 13.4 (2.1); systolic blood pressure 172.6 (27.2) mmHg; intraventricular haemorrhage 745 (32.0%) and prior antiplatelet use 610 (26.2%).
Conclusion: TICH-2 is the largest trial of TXA in spontaneous ICH and recruited over its original target of 2000 patients. The results will be available in May 2018 and will inform whether TXA should be recommended for the treatment of acute spontaneous ICH. |
| first_indexed | 2025-11-14T20:19:35Z |
| format | Conference or Workshop Item |
| id | nottingham-51139 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T20:19:35Z |
| publishDate | 2018 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-511392020-05-04T19:36:31Z https://eprints.nottingham.ac.uk/51139/ Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial Sprigg, Nikola Flaherty, Katie Law, Zhe Kang Appleton, Jason P. Scutt, Polly Krishnan, Kailash Bath, Philip M. Background: Haematoma expansion leads to worse outcome in intracerebral haemorrhage (ICH). Tranexamic acid (TXA) is a promising haemostatic agent to prevent haematoma expansion and improve outcome after ICH. Methods: TICH-2 is a multicentre prospective double blind randomised controlled trial, which recruited patients presenting within 8 hours of primary ICH to receive intravenous TXA or placebo. Primary outcome is modified Rankin Scale at day 90 and will be analysed using ordinal logistic regression, adjusted for minimisation criteria. Secondary outcomes will be analysed using adjusted binary logistic regression and multiple linear regression; these include haematoma expansion at 24 hours, day 7 National Institute of Health Stroke Scale (NIHSS), day 90 Barthel Index, quality of life, cognition and mood. Results: A total of 2325 patients were recruited between 14th March 2013 and 30th September 2017, from 12 countries: United Kingdom (n= 1910), Italy, Georgia, Switzerland, Malaysia, Hungary, Poland, Ireland, Turkey, Sweden, Denmark and Spain. Randomisation characteristics included: age 68.9 (13.8) years; male 1301 (56.0%); time from onset to randomisation 3.6 hours [2.6, 5.0]; NIHSS 13 (7.5); Glasgow coma scale 13.4 (2.1); systolic blood pressure 172.6 (27.2) mmHg; intraventricular haemorrhage 745 (32.0%) and prior antiplatelet use 610 (26.2%). Conclusion: TICH-2 is the largest trial of TXA in spontaneous ICH and recruited over its original target of 2000 patients. The results will be available in May 2018 and will inform whether TXA should be recommended for the treatment of acute spontaneous ICH. 2018-05-16 Conference or Workshop Item PeerReviewed Sprigg, Nikola, Flaherty, Katie, Law, Zhe Kang, Appleton, Jason P., Scutt, Polly, Krishnan, Kailash and Bath, Philip M. (2018) Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial. In: 4th European Stroke Organisation Conference (ESOC 2018), 16-18 May 2018, Gothenburg, Sweden. |
| spellingShingle | Sprigg, Nikola Flaherty, Katie Law, Zhe Kang Appleton, Jason P. Scutt, Polly Krishnan, Kailash Bath, Philip M. Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial |
| title | Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial |
| title_full | Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial |
| title_fullStr | Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial |
| title_full_unstemmed | Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial |
| title_short | Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial |
| title_sort | results from the tranexamic acid for primary intracerebral haemorrhage-2 (tich-2) trial |
| url | https://eprints.nottingham.ac.uk/51139/ |